09:14 AM EST, 02/23/2026 (MT Newswires) -- Health care stocks were mixed premarket Monday, with the iShares Biotechnology ETF (IBB) 0.4% lower and the State Street Health Care Select Sector SPDR ETF ( XLV ) up 0.3%.

Novo Nordisk ( NVO ) shares were down more than 15% after the company said its weight-loss treatment CagriSema failed to achieve the primary endpoint of demonstrating that it wasn't inferior to Eli Lilly's ( LLY ) tirzepatide in a late-stage Redefine 4 study.

Gilead Sciences ( GILD ) said it will acquire Arcellx ( ACLX ) for $7.8 billion, expanding its CAR T-cell therapy offerings. Arcellx ( ACLX ) stock was up more than 78% pre-bell.

ImmunityBio ( IBRX ) shares were up more than 13% after the company reported a narrower Q4 net loss as revenue increased during the period.